Noble David J, Burnet Neil G
1 Department of Oncology, Cancer Research UK VoxTox Research Group, University of Cambridge, Cambridge Biomedical Campus, Addenbrooke's Hospital , Cambridge , UK.
2 Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust , Cambridge , UK.
Br J Radiol. 2018 Jul;91(1087):20170894. doi: 10.1259/bjr.20170894. Epub 2018 May 17.
MR-based image-guided (IG) radiotherapy via all-in-one MR treatment units (MR-linacs) is one of the hottest topics in contemporary radiotherapy research. From ingenious engineering solutions to complex physical problems, researchers have developed machines with the promise of superior image quality, and all the advantages this may confer. Benefits include better tumour visualisation, online adaptation and the potential for image biomarker-based personalised RT. However, it is important to remember that the technical challenges are real. In many instances, they are skillfully managed rather than abolished, a point illustrated by the wide variety of MR-linac designs. The proposed benefits also deserve careful inspection. Better visibility of the primary tumour on an IG scan cannot be bad, but does not automatically equate to better IG, which often depends on a more generalised match to daily anatomy. MR-linac will undoubtedly be a rich milieu to search for IMBs, but these will need to be carefully validated, and similar work with CT-based biomarkers using existing, cheaper, and more widely available hardware is currently ongoing. Online adaptation is an attractive concept, but practicalities are complex, and more work is required to understand which patients will benefit from plan adaptation, and when. Finally, the issue of cost cannot be overlooked, nor can the research community's responsibilities to global healthcare inequalities. MR-linac is an exciting and ingenious technology, which merits both investment and research. It may not, however, have the future to itself.
通过一体化磁共振治疗设备(磁共振直线加速器)进行基于磁共振成像引导(IG)的放射治疗是当代放射治疗研究中最热门的话题之一。从巧妙的工程解决方案到复杂的物理问题,研究人员开发出了有望提供卓越图像质量以及由此可能带来的所有优势的设备。其优势包括更好的肿瘤可视化、在线自适应以及基于图像生物标志物的个性化放疗的潜力。然而,必须记住技术挑战是实实在在存在的。在许多情况下,这些挑战是得到了巧妙应对而非消除,这一点从各种各样的磁共振直线加速器设计中就可以看出来。所宣称的优势也值得仔细审视。在IG扫描中原发肿瘤的更好可视性固然不错,但这并不自动等同于更好的IG,而IG往往取决于与日常解剖结构更普遍的匹配。磁共振直线加速器无疑将是寻找影像组学标志物(IMB)的丰富环境,但这些标志物需要仔细验证,而且目前正在使用现有的、更便宜且更广泛可用的硬件开展基于CT生物标志物的类似工作。在线自适应是一个有吸引力的概念,但实际操作很复杂,还需要开展更多工作来了解哪些患者将从计划自适应中获益以及何时获益。最后,成本问题不能被忽视,研究界对全球医疗保健不平等问题所肩负的责任也不能被忽视。磁共振直线加速器是一项令人兴奋且巧妙的技术,值得投资和研究。然而,它可能并非独领未来。